LCFY vs. NKTR

Last updated Apr 1, 2026

Compare and contrast key facts about Locafy Ltd (LCFY) and Nektar Therapeutics (NKTR).

Performance

LCFY vs. NKTR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Locafy Ltd (LCFY) and Nektar Therapeutics (NKTR). The values are adjusted to include any dividend payments, if applicable.

LCFY vs. NKTR - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
LCFY Locafy Ltd	55.71%	-59.24%	-24.30%	53.82%	-91.17%
NKTR Nektar Therapeutics	70.18%	203.08%	64.60%	-75.00%	-59.79%

Fundamentals

Market Cap LCFY : $7.92M NKTR : $1.46B
EPS LCFY : -$1.44 NKTR : -$10.15
PS Ratio LCFY : 2.18 NKTR : 21.05
PB Ratio LCFY : 2.07 NKTR : 16.26
Total Revenue (TTM) LCFY : $3.63M NKTR : $55.23M
Gross Profit (TTM) LCFY : $3.63M NKTR : $55.04M
EBITDA (TTM) LCFY : -$803.06K NKTR : -$122.97M

Returns By Period

In the year-to-date period, LCFY achieves a 55.71% return, which is significantly lower than NKTR's 70.18% return.

LCFY

• 1D: 3.81%
• 1M: -8.02%
• YTD: 55.71%
• 6M: -40.44%
• 1Y: -3.33%
• 3Y*: -12.37%
• 5Y*: —
• 10Y*: —

NKTR

• 1D: 10.27%
• 1M: 4.31%
• YTD: 70.18%
• 6M: 26.45%
• 1Y: 605.39%
• 3Y*: 89.68%
• 5Y*: -25.14%
• 10Y*: -10.44%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

LCFY vs. NKTR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LCFY

LCFY Risk / Return Rank: 55
LCFY Sharpe Ratio Rank: 40
LCFY Sortino Ratio Rank: 83
LCFY Omega Ratio Rank: 79
LCFY Calmar Ratio Rank: 36
LCFY Martin Ratio Rank: 37

NKTR

NKTR Risk / Return Rank: 98
NKTR Sharpe Ratio Rank: 97
NKTR Sortino Ratio Rank: 99
NKTR Omega Ratio Rank: 97
NKTR Calmar Ratio Rank: 99
NKTR Martin Ratio Rank: 98

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LCFY vs. NKTR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Locafy Ltd (LCFY) and Nektar Therapeutics (NKTR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	LCFY	NKTR	Difference
Sharpe ratio Return per unit of total volatility	-0.01	3.23	-3.24
Sortino ratio Return per unit of downside risk	2.28	5.66	-3.39
Omega ratio Gain probability vs. loss probability	1.28	1.64	-0.36
Calmar ratio Return relative to maximum drawdown	-0.18	11.81	-11.99
Martin ratio Return relative to average drawdown	-0.28	28.66	-28.94
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

LCFY vs. NKTR - Sharpe Ratio Comparison

The current LCFY Sharpe Ratio is -0.01, which is lower than the NKTR Sharpe Ratio of 3.23. The chart below compares the historical Sharpe Ratios of LCFY and NKTR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	LCFY	NKTR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.01	3.23	-3.24
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.21	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.11	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.28	0.01	-0.29

Correlation

The correlation between LCFY and NKTR is 0.10, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

LCFY vs. NKTR - Dividend Comparison

Neither LCFY nor NKTR has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

LCFY vs. NKTR - Drawdown Comparison

The maximum LCFY drawdown since its inception was -96.59%, roughly equal to the maximum NKTR drawdown of -99.61%. Use the drawdown chart below to compare losses from any high point for LCFY and NKTR.

Drawdown Indicators

	LCFY	NKTR	Difference
Max Drawdown Largest peak-to-trough decline	-96.59%	-99.61%	+3.02%
Max Drawdown (1Y) Largest decline over 1 year	-68.07%	-46.54%	-21.53%
Max Drawdown (5Y) Largest decline over 5 years	—	-97.93%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-99.61%	—
Current Drawdown Current decline from peak	-93.47%	-95.58%	+2.11%
Average Drawdown Average peak-to-trough decline	-88.61%	-68.16%	-20.45%
Ulcer Index Depth and duration of drawdowns from previous peaks	43.56%	19.18%	+24.38%

Volatility

LCFY vs. NKTR - Volatility Comparison

Locafy Ltd (LCFY) has a higher volatility of 22.77% compared to Nektar Therapeutics (NKTR) at 16.98%. This indicates that LCFY's price experiences larger fluctuations and is considered to be riskier than NKTR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LCFY	NKTR	Difference
Volatility (1M) Calculated over the trailing 1-month period	22.77%	16.98%	+5.79%
Volatility (6M) Calculated over the trailing 6-month period	70.56%	65.60%	+4.96%
Volatility (1Y) Calculated over the trailing 1-year period	253.09%	189.57%	+63.52%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	179.42%	121.46%	+57.96%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	179.42%	96.96%	+82.46%

Financials